At EuroEcho, Ebit (Esaote Group) presents the world premiere of ZEfiRO, the new “cloud-native” PACS for the SUITESTENSA platform, redefining its design philosophy
13 déc. 2024 07h25 HE | Esaote
BERLIN and GENOA, Italy, Dec. 13, 2024 (GLOBE NEWSWIRE) -- EBIT s.r.l., the Esaote Group company that leads the Information Technology sector in the Healthcare field, is presenting the world...
cmi_logo.png
[Latest] Global Dry Eye Syndrome Treatment Market Size/Share Worth USD 12,281.4 Million by 2033 at a 7.1% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
11 déc. 2024 12h30 HE | Custom Market Insights
Austin, TX, USA, Dec. 11, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Dry Eye Syndrome Treatment Market Size, Trends and Insights By Type (Evaporative...
cmi_logo.png
[Latest] Global Epilepsy Treatment Devices Market Size/Share Worth USD 787.3 Million by 2033 at a 4.1% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
19 nov. 2024 11h30 HE | Custom Market Insights
Austin, TX, USA, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Epilepsy Treatment Devices Market Size, Trends and Insights By Product Type...
Tremfya's Promising
Tremfya's Promising Debut Boosts Momentum for IL-23 Class in Ulcerative Colitis Treatment, According to Spherix Global Insights
15 nov. 2024 09h38 HE | Spherix Global Insights
EXTON, PA, Nov. 15, 2024 (GLOBE NEWSWIRE) -- In what has been a transformative year for ulcerative colitis (UC) treatment, the IL-23 class has solidified its role as a key therapeutic treatment...
Logo.png
Palisade Bio Announces First Subject Dosed in Phase 1 Clinical Study of PALI-2108 for the Treatment of Moderate-to-Severe Ulcerative Colitis (UC)
07 nov. 2024 08h30 HE | Palisade Bio, Inc.
Carlsbad, CA, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade,” “Palisade Bio” or the “Company”), a biopharmaceutical company focused on developing and advancing...
SERMONIX NEW LOGO JPEG (2).jpg
Sermonix Surveys Find Vaginal/Sexual Health Symptoms Are Among Most Significant Issues Affecting Lives of ER+/HER2- Metastatic Breast Cancer Patients
02 nov. 2024 09h00 HE | Sermonix Pharmaceuticals Inc.
COLUMBUS, Ohio, Nov. 02, 2024 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat metastatic breast...
Logo.png
Palisade Bio Announces Positive Data from Two Ex Vivo Translational Studies of PALI-2108 for the Treatment of Ulcerative Colitis
31 oct. 2024 08h30 HE | Palisade Bio, Inc.
Targeted, better-tolerated oral PDE4 inhibitors are an unmet need in inflammatory bowel disease (IBD) PALI-2108 demonstrates in ex vivo studies; targeted activation and reduced side effects,...
Soligenix_Logo.jpg
Soligenix, Inc. to Present at the 2024 ThinkEquity Conference
24 oct. 2024 07h30 HE | Soligenix, Inc.
Soligenix, Inc. to Present at the 2024 ThinkEquity Conference
Logo.png
Ocean Biomedical, Inc. Announces Receipt of Nasdaq Staff Determination Letter
22 oct. 2024 16h45 HE | Ocean Biomedical, Inc.
PROVIDENCE, Rhode Island, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA), today announced that on October 16, 2024, it received a Staff Determination Letter from The Nasdaq...
Funds urgently needed to support frontline heroes in a difficult world
15 oct. 2024 10h55 HE | Primary Care Trauma Foundation
The Primary Care Trauma Foundation (PCTF) is a global charity that trains medics & lay volunteers to prepare for when the worst happens all over the world.